Compositions and methods of making a photoactive agent
AssigneePurdue Pharmaceutical Products L.P.
InventorsLeon Xu, Alexander J. Pallenberg
Life of this patent
Estimating the term…
Loading patent…
AssigneePurdue Pharmaceutical Products L.P.
InventorsLeon Xu, Alexander J. Pallenberg
Estimating the term…
An improved two stage reaction process for production of mono-L-aspartyl chlorin e6. In a first stage, the activation reaction between chlorin e6 and a carbodiimide produces a previously unknown anhydride in an activation reaction product. This reaction product is purified to remove a significant proportion of the precursors of di-L-aspartyl chlorin e6. The purified activation reaction product contains a higher concentration of the previously unknown anhydride. This purified reaction product is used in a second stage: a coupling reaction of the purified activation reaction product with aspartate. The coupling reaction produces a coupling reaction product that has significantly reduced di-L-aspartyl chlorin e6 concentration. This reduced di-L-aspartyl chlorin e6 concentration facilitates purification of mono-L-aspartyl chlorin e6 from the coupling reaction mixture.
1-8. (canceled)
A process for preparing a chlorin e6 anhydride, or a pharmaceutically acceptable salt thereof, the process comprising:
12-13. (canceled)
16-17. (canceled)
A method for preparing mono-L aspartyl chlorin e6, or a pharmaceutically acceptable salt thereof, the method comprising:
A method of preparing Talaporfin Sodium, the method comprising preparing a purified intermediate reaction mixture from a crude reaction mixture comprising chlorin e6, chlorin e6 anhydride, and precursors of diaspartyl chlorin e6 wherein preparing the purified intermediate reaction mixture comprises removing a significant proportion of the precursors of diaspartyl chlorin e6.
30-35. (canceled)
A process for preparing a mono-amino acid chlorin e6, or a pharmaceutically acceptable salt thereof, comprising:
45-56. (canceled)
Dependencies are inferred from the claim text.